Controversies in the management of localized prostate cancer: Radical prostatectomy still the standard of care

Critical Reviews in Oncology/Hematology

Volumn 84, Issue SUPPL. 1, 2012, Pages e24-e29

  Budäus, Lars ^a   Huland, Hartwig ^a   Graefen, Markus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Functional outcomes; Oncological outcomes; Prostate cancer; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; BIOCHEMICAL RECURRENCE FREE SURVIVAL; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; HUMAN; INTENSITY MODULATED RADIATION THERAPY; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SURGICAL TECHNIQUE; TREATMENT OUTCOME; WATCHFUL WAITING;

EID: 84871687892     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.09.004     Document Type: Review

References (49)

1. Society A.C. Detailed guide: prostate cancer 2010, Available at www.cancer.org [accessed 08.04.10].
2. Walsh P.C., DeWeese T.L., Eisenberger M.A. Clinical practice. Localized prostate cancer. N Engl J Med 2007, 357(December (26)):2696-2705.
3. Cooperberg M.R., Broering J.M., Litwin M.S., et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the Prostate Strategic Urologic Research Endeavor (CapSURE), a National Disease Registry. J Urol 2004, 171(April (4)):1393-1401.
4. Cooperberg M.R., Broering J.M., Carroll P.R. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010, 28(March (7)):1117-1123.
5. Walsh P.C. 2008 Whitmore lecture: radical prostatectomy-where we were and where we are going. Urol Oncol 2009, 27(May-June (3)):246-250.
6. Ficarra V., Novara G., Artibani W., et al. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol 2009, 55(May (5)):1037-1063.
7. Budaus L., Isbarn H., Schlomm T., et al. Current technique of open intrafascial nerve-sparing retropubic prostatectomy. Eur Urol 2009, 56(August (2)):317-324.
8. Yossepowitch O., Bjartell A., Eastham J.A., et al. Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol 2009, 55(January (1)):87-99.
9. Graefen M., Walz J., Huland H. Open retropubic nerve-sparing radical prostatectomy. Eur Urol 2006, 49(January (1)):38-48.
10. Walz J., Burnett A.L., Costello A.J., et al. A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy. Eur Urol 2010, 57(March (2)):179-192.
11. Bill-Axelson A., Holmberg L., Filen F., et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008, 100(August (16)):1144-1154.
12. Porter C.R., Gallina A., Kodama K., et al. Prostate cancer-specific survival in men treated with hormonal therapy after failure of radical prostatectomy. Eur Urol 2007, 52(August (2)):446-452.
13. Isbarn H., Wanner M., Salomon G., et al. Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era. BJU Int 2009, (December).
14. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360(July (9327)):103-106.
15. Freedland S.J., Partin A.W., Humphreys E.B., Mangold L.A., Walsh P.C. Radical prostatectomy for clinical stage T3a disease. Cancer 2007, 109(April (7)):1273-1278.
16. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Acta Urol Esp 2009, 33(February (2)):113-126.
17. Hsu C.Y., Joniau S., Oyen R., Roskams T., Van Poppel H. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol 2007, 51(January (1)):121-128. [discussion 128-9].
18. Ward J.F., Slezak J.M., Blute M.L., Bergstralh E.J., Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005, 95(April (6)):751-756.
19. Van Poppel H., Vekemans K., Da Pozzo L., et al. Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001). Eur J Cancer 2006, 42(May (8)):1062-1067.
20. Bolla M., de Reijke T.M., Van Tienhoven G., et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009, 360(June (24)):2516-2527.
21. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997, 337(July (5)):295-300.
22. Vickers A.J., Bianco F.J., Serio A.M., et al. The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst 2007, 99(August (15)):1171-1177.
23. Ciezki J.P., Klein E.A. Brachytherapy or surgery? A composite view. Oncology (Williston Park) 2009, 23(October (11)):960-964.
24. Rayala H.J., Richie J.P. Radical prostatectomy reigns supreme. Oncology (Williston Park) 2009, 23(September (10)):863-867.
25. Chun F.K., Steuber T., Erbersdobler A., et al. Development and internal validation of a nomogram predicting the probability of prostate cancer Gleason sum upgrading between biopsy and radical prostatectomy pathology. Eur Urol 2006, 49(May (5)):820-826.
26. Grossfeld G.D., Chang J.J., Broering J.M., et al. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J Urol 2001, 165(March (3)):851-856.
27. Joniau S., Hsu C.Y., Lerut E., et al. A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. Eur Urol 2007, 51(February (2)):388-394. [discussion 386-95].
28. Engel J., Bastian P.J., Baur H., et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 2010, (January).
29. Steuber T., Budäus L., Walz J., et al. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study. BJU Int. 2010, [Epub ahead of print] Oct 13. 10.1111/j.1464-410X.2010.09730.x.
30. Briganti A., Karnes J.R., Da Pozzo L.F., et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2009, 55(February (2)):261-270.
31. Schumacher M.C., Burkhard F.C., Thalmann G.N., Fleischmann A., Studer U.E. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 2008, 54(August (2)):344-352.
32. Nguyen P.L., D'Amico A.V., Lee A.K., Suh W.W. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 2007, 110(October (7)):1417-1428.
33. Simmons M.N., Stephenson A.J., Klein E.A. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol 2007, 51(May (5)):1175-1184.
34. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005, 294(July (4)):433-439.
35. Van Der Poel H.G., Moonen L., Horenblas S. Sequential treatment for recurrent localized prostate cancer. J Surg Oncol 2008, 97(April (5)):377-382.
36. Sandler H.M., Mirhadi A.J. Radical radiotherapy for prostate cancer is the 'only way to go'. Oncology (Williston Park) 2009, 23(September (10)):840-843.
37. Peeters S.T., Heemsbergen W.D., Koper P.C., et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68Gy of radiotherapy with 78Gy. J Clin Oncol 2006, 24(May (13)):1990-1996.
38. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005, 294(September (10)):1233-1239.
39. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70(January (1)):67-74.
40. Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358(March (12)):1250-1261.
41. Widmark A., Klepp O., Solberg A., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009, 373(January (9660)):301-308.
42. Keating N.L., O'Malley A.J., Freedland S.J., Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010, 102(January (1)):39-46.
43. Bauer R.M., Bastian P.J., Gozzi C., Stief C.G. Postprostatectomy incontinence: all about diagnosis and management. Eur Urol 2009, 55(February (2)):322-333.
44. Potosky A.L., Davis W.W., Hoffman R.M., et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 2004, 96(September (18)):1358-1367.
45. Miller D.C., Sanda M.G., Dunn R.L., et al. Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy. J Clin Oncol 2005, 23(April (12)):2772-2780.
46. Begg C.B., Riedel E.R., Bach P.B., et al. Variations in morbidity after radical prostatectomy. N Engl J Med 2002, 346(April (15)):1138-1144.
47. Birkmeyer J.D., Dimick J.B. Understanding and reducing variation in surgical mortality. Annu Rev Med 2009, 60:405-415.
48. Vickers A.J., Savage C.J., Hruza M., et al. The surgical learning curve for laparoscopic radical prostatectomy: a retrospective cohort study. Lancet Oncol 2009, 10(May (5)):475-480.
49. Eichelberg C., Erbersdobler A., Haese A., et al. Frozen section for the management of intraoperatively detected palpable tumor lesions during nerve-sparing scheduled radical prostatectomy. Eur Urol 2006, 49(June (6)):1011-1016. [discussion 1016-18].